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A CROSS SECTIONAL ANALYSIS OF THE ASSOCIATION BETWEEN FGF19 
TUMOR EXPRESSION AND SERUM AFP LEVELS IN ADVANCED HCC 
PATIENTS 
 
CORINNE CLIFFORD 
ABSTRACT 
Purpose:  HCC is a complicated disease with high mortality rates and limited treatment 
options.  No universal clinical or molecular classification established to inform better 
treatment options.  There has been very limited success in determining a molecular 
profile that represent valid drivers in HCC patients and thus no targeted agents have 
obtained marketing approval.  However, emerging data suggest the FGF19-pathway as a 
HCC driver and a potential therapeutic target. This research study aims to investigate 
whether the HCC prognostic risk factor, serum AFP, is predictive of FGF19 protein 
expression as assessed by immunohistochemistry in advanced HCC patients.   
Methods:  A cross-sectional analysis was performed from baseline data collected in a 
Phase 1 study conducted at various centers across the US, EU, and Asia.  Only advanced 
HCC patients with adequate liver function were eligible for enrollment.  Demographic 
data, detailed history of HCC, and any prior treatments or surgeries were recorded.  
Baseline laboratory values and prognostic factors including performance status (ECOG), 
lab values (i.e. bilirubin, albumin), and the number, size and biomarker status of the 
tumor(s) were collected.  Differences between groups were assessed by t test, or Chi-
square test, as appropriate. Multivariate logistic stepwise regression analyses were 
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performed including all parameters with highly significant correlations in the multivariate 
analysis.  
Results:  Only AFP, metastatic disease, and prior surgery met the criteria to be 
incorporated into the final model. Results indicated that high AFP had a statistically 
significant (p-value = .01) positive association (Wald chi-square statistic = 6.601) with 
positive FGF19 IHC status.  The odds ratio for being FGF19 IHC+ was 12.216 among 
the high AFP subjects as compared to low AFP subjects, and also statistically significant 
but had a very wide 95% confidence interval (1.811, 82.79).   
Conclusions:  The results indicated that HCC patients with high serum AFP levels have a 
twelve fold higher chance of having a positive FGF19 IHC status than those with low 
AFP levels.  Further studies are warranted in order to replicate the data in a larger sample 
size to understand future clinical implications once treatment options become available 
for FGF19 IHC positive patients.   
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INTRODUCTION 
Background 
Hepatocellular Carcinoma  
Hepatocellular carcinoma (HCC) is the most common form of primary liver 
cancer.  Most HCC patients (70%–90%) have underlying chronic liver disease and 
cirrhosis related to co-morbid conditions such as hepatitis B virus (HBV) infection, 
hepatitis C virus (HCV) infection, alcoholic liver disease, or nonalcoholic steatohepatitis 
(NASH).1 However, the prevalence of co-morbid conditions varies greatly between 
western and eastern populations.1  For example, approximately 50% of HCC cases 
worldwide are associated with HBV compared to 10-15% in the US, whereas about half 
HCC patients in the US are infected with HCV compared to 25% worldwide.2,3   
Liver cancer is one of the most common cancers worldwide (5th) and is only 
second to lung cancer in the number of cancer related deaths every year.4 In 2012, the 
annual incidence globally was estimated to be approximately 782,000 cases, with a 
mortality rate of approximately 746,000 per year.4   As shown in Table 1, there is a 
distinct distribution of the malignancy across geographic locations, with the highest 
incidence, prevalence, and mortality rates (by far) in China due to the high prevalence of 
HBV and HCV.4   
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Table 1: 2012 Liver Cancer Estimated Incidence, Prevalence, and Mortality by Region4  
Estimated 
Numbers 
(thousands)2 Men Women Both Sexes 
Geographic 
Locations 
Cases Deaths Cases Deaths 5-year 
Prevalence 
Africa  25 24 14 12 26 
US 23 17 8 7 27 
China 293 282 101 101 291 
India 17 17 10 10 13 
EU 36 32 16 17 47 
 
Prognosis for these patients is extremely poor with an overall mortality to 
incidence ratio of 0.952.4 Despite all the advances in cancer research and development 
over recent years, HCC remains a high unmet medical need with its increasing number of 
cases each year and high mortality rates. The additional complexity of the decompensated 
liver combined with the malignant tumor(s), make HCC a difficult malignancy to 
diagnose and treat at an early cancer stage.    
Treatment Options for HCC 
The only curative treatments for HCC are by liver transplantation or surgical 
resection of the liver tumor(s).5 Most patients are not considered good candidates for 
these surgeries due to the advanced stage of HCC at diagnosis or degree of liver 
decompensation due to the underlying cirrhosis.5 Even for the few patients who are good 
candidates, recurrence rates are unfavorable (20% for transplants and 50% for 
resections).6,7  Other treatment options include localized therapies, which have shown 
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some long term success.  These include radiofrequency ablation, trans-arterial 
chemoembolization (TACE), and radioembolization, but have only been effective for 
treating a select group of HCC patients.8   
Non-surgical options for treating other malignancies usually include 
chemotherapy or systemic therapy.  Unfortunately, HCC is known to be a cancer type 
that is one of the most resistant to chemotherapy treatment options.  Currently, sorafenib, 
a multi-kinase inhibitor, is the only drug approved for systemic treatment of HCC. 5,9 
Additionally, sorafinib has a very low response rate (~2%) and was only shown to 
improve overall survival (OS) in pivotal trials by a meager 2.8 months.8,9 Even with 
sorafinib treatment, survival duration is still less than a year (10.7 months).8 Since its 
approval in 2007, no other therapies, including targeting agents, have been able to show 
clinically significant improvement in OS; consequently HCC remains a cancer that has a 
significant unmet medical need for better and more treatment options.   
HCC Staging and Prognosis 
Accurately staging cancer patients is essential regardless of the oncological 
indication.  It contributes to prognosis, can help guide treatment decisions, and also 
informs clinical, epidemiologic, and health services research.10 Staging HCC patients is 
more complex than other solid tumor cancers due to cirrhosis and diversity of the 
underlying disease etiology.11  Additionally, the lack of universal acceptance as how to 
best classify HCC patients poses another challenge. However most systems developed 
over the past 50 years do possess one commonality; they all account for both 
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characteristics of the tumor(s) as well as the overall health of the liver as the result of the 
underlying liver disease. 11    
The goal of staging is to classify patients according to certain characteristics in 
order to define prognosis and guide  treatment.12 Important variables considered include 
the patient’s overall health (i.e. performance status), tumor burden (i.e. size, number, 
presence of metastases), clinical symptoms (i.e. abdominal pain), liver function (i.e. 
AST/ALT levels), and presence of any other comorbidities.13  As mentioned previously, 
the degree of liver damage is an important part of classifying HCC patients, as measured 
by Child’s Pugh status.  Child’s Pugh scores were not initially designed for cirrhosis 
assessments, but instead used to predict the risk of mortality during surgery.14 Since the 
original development, it has been modified and is broadly used to assess the prognosis of 
chronic liver disease and cirrhosis.14 It is calculated by measuring total bilirubin, serum 
albumin, and prothrombin time (prolongation) as well as the presences and severity 
ascites and hepatic encephalopathy.14 
 The current staging classification systems have many limitations.  They have 
been based upon a population balanced between early and advanced staged HCC 
patients.15 Characteristics may vary if examining only advanced staged patients, 
consequently it may be more informative to separate the two.15  Furthermore, it’s not 
clear whether additional variables that differ between these systems provide significant 
prognostic value.15 Since patients diagnosed with HCC with earlier-stage disease are 
much more likely to receive potentially curative treatment, it is important to be able to 
identify these patients early on and classify these patients consistently and correctly.14   
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Additionally, no clear molecular or genetic profiles have been identified to show 
prognostic value in HCC.16 There has been success in identifying these types of markers 
or mutations in other oncologic indications such as breast and lung cancer, but it has not 
yet translated to HCC.16 Treatment options in these patients are more defined and 
effective if they are positive for a particular marker.  Additional research in HCC could 
yield molecular or genetic profiles that become the basis for a new HCC staging system; 
one that effectively separates patients into subgroups with homogeneous prognosis and 
response to treatment, which could aid in the selection of treatment.16  
Role of Alpha-fetoprotein in HCC 
Alpha-fetoprotein (AFP) was first recognized as a marker for HCC over 40 years 
ago, but its clinical implications are not entirely clear.17 It is one of the most abundant 
proteins present in fetal development that sharply declines after birth; therefore any 
elevations in adults could be indicative of underlying malignancy.8 Specifically, AFP is 
made by the yolk sac and the liver during gestation which could provide insight as to why 
it later emerged as a means to detect HCC preclinically.8 However, clinical studies have 
provided mixed results regarding the link to serum AFP elevations in diagnosing adults 
with HCC.8   
Measuring AFP is relatively simple and is routinely used for HCC surveillance, 
and has been used in evaluating prognosis and monitoring recurrence following 
treatment.18 Studies have shown that elevated AFP levels in HCC patients is associated 
with decreased survival or a poor outcome; however, it is not as clear which is the driver 
after adjusting the analysis for tumor size.19 Findings suggest there is a complex 
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interaction with other risk factors for HCC since high AFP values are also correlated with 
other major clinical factors including age, HBV related HCC, tumor size, and vascular 
invasion. 19 Additionally, AFP serum levels can also be increased in patients with other 
non-malignant liver disorders.19 
One large study investigated the presence or absence of any malignancy among 
adults with elevated AFP levels (>20 ng/ml) and found that 68% had a malignancy (most, 
but not all HCC) while 32% did not have nor develop any malignancy.18 For reference, 
both AFP levels of 20 and 400 ng/mL are considered feasible cutoffs for predicting 
outcome in HCC patients.20  The mean serum AFP level of HCC patients identified in 
this study was 1,030 ng/ml (SD +/- 1,890) with a range of 20 to 3,268 ng/ml.18 
Conversely among patients diagnosed with HCC, some possessed high serum levels, 
however, approximately 30% had normal levels that were maintained over the course of 
their disease.17   
Fibroblast Growth Factor 19 Tumor Expression in HCC patients 
Fibroblast growth factor 19 (FGF19) is a protein produced in the small intestine 
that regulates bile acid synthesis in the liver.  Normal liver does not express the FGF19 
protein; therefore, any expression is a tumor marker.21 Preclinical studies investigating 
FGF19 protein levels in mice have shown that genomic amplification and/or over-
expression was associated with the development of HCC and has been implicated to play 
a similar role in humans. 21  
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Figure 1: FGF19 Role in Normal Liver and in HCC Liver22  
  
The function of FGF19 in normal liver vs. a liver with FGF19 driven HCC is 
depicted in Figure 1.  It is estimated that about 20-30% of HCC tumors have aberrant 
FGF19 expression.21  A list of drugs currently in development to treat HCC by targeting 
the FGFR4/FGF19 pathway are listed in Table 2.   
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Table 2: FGFR4/FGF19 Inhibitors in Development23 
NCT Number Protocol Title Intervention Sponsor Phase 
NCT02325739 
FGF401 in HCC and Solid Tumors 
Characterized by Positive FGFR4 and 
KLB Expression 
Drug: 
FGF401 Novartis  1/2 
NCT02690350 An Open Study Assessing the Safety and Tolerability of U3-1784 
Drug: U3-
1784 
Daiichi Sankyo 
Inc. 1 
NCT02834780 
Phase 1 Study to Evaluate the Safety, 
Pharmacokinetics and Pharmacodynamics 
of H3B-6527 in Subjects With Advanced 
HCC 
Drug: H3B-
6527 
H3 Biomedicine/ 
Eisai  1 
NCT02508467 A Phase 1 Study of BLU-554 in Patients With HCC 
Drug: BLU-
554 
Blueprint 
Medicines 1 
 
Study Rationale and Purpose 
Since HCC patients have such a poor survival rate, striving to better characterize 
and classify them is imperative to identify potential subsets that may gain substantial 
benefit from any new interventions in development.11 Therefore this study aims to 
investigate whether AFP levels are different in FGF19 over-expressed advance stage 
HCC patients.  This could provide additional information to further investigate its 
prognostic value in this subset of HCC patients and whether this difference can help 
guide better treatment decisions. Specifically, the association between high serum AFP 
levels and FGF19 tumor expression in patients with advanced HCC will be investigated.   
Study Question 
Are high serum AFP levels associated with tumor FGF19 protein expression as assessed 
by IHC in patients with advanced HCC?   
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Study Objectives 
To determine whether serum AFP levels were predictive of FGF19 IHC tumor status in 
HCC patients. 
Study Endpoints/Outcomes of Interest 
The “exposure” or outcome variable was tumor FGF19 IHC tumor expression status and 
the primary risk factor or predictor variable for this study was AFP levels.   
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METHODS 
Study Design  A cross-sectional analysis was performed from baseline data collected in a Phase 
1 study conducted at various centers (21) across the US, EU, and Asia as shown in Figure 
2.  The trial was approved at the local Institutional Review Board or Ethics Committee 
prior to study initiation and all patients provided written informed consent prior to any 
study specific procedures.   
Figure 2: Phase 1 Study Design 
 
Study Population A total of 52 patients were enrolled at the time of analysis.  Only patients 18 years or older with advanced HCC, adequate liver function (Child Pugh score 5-6 points, class A), and good performance status (ECOG 0-1) were enrolled in the study.  Patients must have failed, refused, or did not have access to sorafenib.  Patients were excluded if they underwent liver transplant or if they were candidates for liver transplant or resection.  Details of laboratory exclusion criteria are shown in Table 3.  
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Table 3: Key Exclusionary Values 
Test Value 
Platelet count  <75 × 109/L 
Absolute neutrophil count  <1.0 × 109/L 
Hemoglobin <8.0 g/dL 
Aspartate aminotransferase (AST)  >5 × the upper limit of normal (ULN) 
Alanine aminotransferase (ALT) >5 × the ULN 
Total bilirubin >2.5 mg/dL 
Prothrombin time  >6 seconds above control 
Measured creatinine clearance <40 mL/min 
QT interval corrected using Frederica’s 
formula  
>450 msec  
Data Collection 
Demographic data such as age, race, and gender were recorded electronically 
using meditata RAVE EDC database.  Detailed history of HCC and any prior treatments 
or surgeries were collected for all subjects.  Baseline blood count, AFP levels, 
performance status (ECOG), lab values (i.e. AST, ALT, alkaline phosphatase (ALP), 
bilirubin, albumin, etc.), tumor characteristics (i.e. the number, size, etc.), and FGF19 
tumor expression levels were also recorded.  All tests were performed locally per the 
site’s local standards, except FGF19 tumor status was determined by central laboratory 
immunohistochemistry (IHC) testing.  FGF19 IHC tumor status was reported by percent 
positivity and positive/negative based on a 1% cutoff.   
Statistical Analysis 
Data were summarized using descriptive statistics.  Continuous data variables 
were described by N, mean, standard deviation, minimum, and maximum. Categorical 
data variables were shown using the number and percentage (N, %) of patients within 
each classification.  All statistical analyses were performed using SAS version 9.4. 
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Initially, to understand the correlation between AFP and FGF19, a linear 
regression model was built to explore whether the FGF19 IHC value was predictable by 
AFP value.   Both FGF19 IHC results and AFP levels were treated as continuous 
variables in the initial linear regression model.  The outcome/ dependent variable was 
FGF19, while AFP served as the predictor/independent variable.  A t-test was used to 
show whether the relationship was significant.  A p-value < 0.05 was considered 
statistically significant.  
A logistic regression model was built using FGF19 IHC as a binary outcome 
variable (positive or negative) and AFP as a continuous predictor variable.  Odds ratios 
estimates were calculated with 95% Wald confidence intervals.  By dichotomizing 
FGF19 IHC levels, univariate logistic regression analysis was then conducted to examine 
its association with various HCC risk factors. For those variables exhibiting a significant 
association in univariate logistic regression analysis, multivariate logistic stepwise 
regression analysis was then built.  
Variables selected by the multivariate stepwise logistic regression model were 
further examined in the final model.  Group comparisons were conducted using the chi-
square test. Odds ratios estimates were calculated with 95% Wald confidence intervals.  
A p-value < 0.05 was considered statistically significant.    
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RESULTS 
Study Population 
 From September 2015 to February 2017, a total of 52 patients with advanced 
HCC were enrolled at 11 centers in Hong Kong, Singapore, South Korea, Spain, the 
United Kingdom, and the US.  Of these patients, only 45 were eligible for analysis in this 
study as detailed in Figure 3.  
Figure 2: Eligibility Profile 
  
Baseline characteristics are described in Table 4. The average age in this subject 
population was 60 years old, and comprised of mostly white or Asian men.  Over half of 
the subjects had a history of underlying hepatitis B or C, while all had advanced disease 
as indicated by the average number of lesions (about 3), largest diameter of target lesion 
(~6 cm), and metastatic disease (78%).  The majority of subjects (78%) also had 
metastatic disease, but with preserved liver function (i.e. all subjects are Child’s Pugh A) 
as shown by the mean averages of liver function lab values.  Of the subjects who were 
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evaluable for analysis, 47% were found to be FGF19 IHC positive as defined by a cutoff 
of 1% or higher.  Also, the proportion of subjects with high serum AFP levels was similar 
to what has been reported previously (67% vs. 68%) indicating that this study cohort was 
representative of the HCC population.   
 
Table 4: Patient Demographics (N=45) 
Category Frequency 
N  % Total 
Sex Male 38 84.4 
Female 7 15.6 
Race Asian 22 48.9 
Black/African 
 
1 2.2 
White 21 46.7 
Unknown 1 2.2 
Etiology HBV 22 48.9 
HCV 4 8.9 
Non-Viral 11 24.4 
Unknown 8 17.8 
ECOG 0 7 15.6 
1 38 84.4 
FGF19 IHC Results Positive 21 46.7 
Negative 24 53.3 
Metastatic Disease No 10 22.2 
Yes 35 77.8 
Vascular Invasion No 21 46.7 
Yes 11 24.4 
Unknown 13 23.9 
  Mean (SD) Min, Max 
Age  59.8(15.6) 18, 85 
Target Lesions Number 2.8 (1.1) 1, 5 
Largest (cm) 5.7 (2.9) 2.1,14.2 
AFP (ng/mL)  11,907.9 (34,282.3) 2.2, 192084 
Laboratory Values ALT (IU/L) 46.9 (32.2) 7, 167 
AST (IU/L) 61.3 (36.4) 10, 162 
ALP (IU/L) 233.4 (245.7) 35, 1178 
Bilirubin (umol/L) 14 (8.2) 5, 39.3 
Albumin (g/L) 39 (3.9) 32, 49 
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Linear Regression Analysis 
FGF19 IHC and AFP values were treated as continuous variables in the linear 
regression analysis.  The range in FGF19 IHC results for the 45 subjects included in the 
analysis are detailed in Table 5. Of the patients who were FGF19 IHC+, most were either 
1% or 15% positive.   
Table 5: FGF19 IHC Results 
FGF19 IHC 
Results (% ) 
N (45) % Total 
0 24 53.3 
1 8 17.8 
2 2 4.4 
3 1 2.2 
5 1 2.2 
7 1 2.2 
15 5 11.1 
25 1 2.2 
50 1 2.2 
60 1 2.2 
 
Linear regression results show that there was a statistically significant positive 
relationship between AFP levels and FGF19 IHC values (p value = 0.0005).  Upon 
evaluation of the fit plot of the linear regression model as shown on the left in Figure 3, 
there was one data point that was an outlier that could potentially be driving the line in an 
upward linear direction.  Consequently, the model was rerun excluding the outlier value 
as shown on the right in Figure 4, and the relationship no longer held.  The fit plot line no 
longer supported a positive relationship; it was slightly negative and not statistically 
significant (p value = 0.53).    
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Figure 3: Fit Plot of FGF19 IHC vs. AFP Value  
 
Logistic Regression Analysis 
As previously mentioned, FGF19 IHC results were reported as positive or 
negative as defined by a 1% cutoff.  Using FGF19 IHC status as a binary outcome 
variable and AFP as a continuous predictor variable, a logistic regression model was run 
to analyze the relationship between the two.  Odds ratio estimates showed no association 
and the results were not statically significant (p value = 0.42).  
Univariate Logistic Regression Analysis 
Based on a cutoff of 20 ng/mL, AFP levels were grouped and treated as a binary 
predictive variable, then categorized by FGF19 IHC status as shown in Table 6.  
Table 6: Serum AFP levels by FGF19 IHC Status 
 Serum AFP Levels (N, % total) 
FGF19 IHC Status ≤20 ng/mL  >20 ng/mL Total 
Positive  3 (6.7) 18 (40.0) 21 (46.7) 
Negative 12 (26.7) 12 (26.7) 24 (53.3) 
Total 15 (33.3) 30 (66.7) 45 
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A univariate logistic regression of FGF19 on categorical AFP was performed and 
analysis results are shown in Table 7.  In addition to AFP, the model was run using 
various HCC risk factors against FGF19 IHC status.     
Table 7: Univariate Analysis of FGF19 IHC Status vs. HCC Risk Factors 
Variable 
Point 
Estimate 
Standard 
Error 
Wald Chi-
Square 
P-value 
Odds 
Ratio 
95% Confidence 
Interval (min, max) 
AFP  0.896 0.373 5.789 0.016 6.000 1.392, 25.857 
Age -0.008 0.020 0.170 0.681 0.992 0.955, 1.031 
Albumin 0.099 0.081 1.480 0.224 1.104 0.942, 1.294 
ALP 0.001 0.001 0.793 0.373 1.001 0.999, 1.004 
ALT -0.002 0.009 0.044 0.833 0.998 0.980, 1.107 
AST -0.004 0.008 0.272 0.602 0.996 0.980, 1.012 
Bilirubin -0.010 0.037 0.072 0.788 0.990 0.921, 1.065 
Etiology- HCV 9.030 168.000 0.003 0.957 >999.999 <0.001, >999.999 
Etiology -Non -viral  -2.621 56.008 0.002 0.963 1.050 0.159, 6.924 
Etiology- HBV -3.740 56.007 0.005 0.947 0.343 0.064, 1.829 
ECOG – 0  0.091 0.415 0.048 0.826 1.200 0.236, 6.105 
Largest Target Lesion Size  0.002 0.010 0.043 0.836 1.002 0.982, 1.023 
Number target lesions 0.405 0.300 1.822 0.177 1.499 0.833, 2.699 
Metastatic- N -0.626 0.386 2.635 0.104 0.286 0.063, 1.296 
Prior Surgery- N 0.549 0.380 2.094 0.148 3.000 0.677, 13.285 
Race – Black  10.121 130.300 0.006 0.938 >999.99 <0.001,>999.99 
Race - UNK  -10.299 130.300 0.006 0.937 <0.001 <0.001,>999.99 
Race –Asian  -0.649 58.286 0.000 0.991 0.229 0.063, 0.826 
Sex  0.091 0.415 0.048 0.826 1.200 0.236, 6.105 
Vascular Invasion –No 0.738 0.425 3.014 0.083 5.333 1.069, 26.613 
Vascular Invasion – UNK  0.199 0.461 0.186 0.666 3.111 0.559, 17.330    Only AFP levels showed a statistically significant association for FGF19 IHC 
status (p-value = 0.016) by Wald Chi-square test, and the odds ratio was also significant 
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(lower limit 1.392).  There was a trend for a positive association of vascular invasion to 
FGF19 IHC status with a p-value of 0.083 with the odds ratio being significant (lower 
limit 1.069).   
Multivariate Stepwise Logistic Regression Analysis 
A stepwise logistic regression model was built including all HCC risk factors 
investigated from Table 7.  In order for a variable to be selected into the model it must be 
significant at 0.1 level, and the significant level of 0.2 to stay in the model. Age, sex, 
race, ECOG, vascular invasion, etiology largest tumor diameter, total lesion size, 
albumin, ALT, AST, ALP, and bilirubin were excluded from the stepwise selection.  
AFP, metastatic disease, and prior surgery were selected into the model.   
Multivariate Stepwise Logistic Regression Analysis – Final Model 
The Final Model was run after the stepwise regression with results shown in 
Table 8.  The final model included the 3 variables selected in the stepwise regression: 
AFP, metastatic disease, and prior surgery.  All were binary high/low (AFP), yes/no 
(metastatic disease and prior surgery), or positive/negative (FGF19 IHC status).    
Table 8: Multivariate Analysis of FGF19 IHC Status vs. HCC Risk Factors 
Parameter 
Analysis of Maximum Likelihood Estimates Odd’s Ratio Estimate 
Estimate Standard 
Error 
Wald 
Chi-Square 
P-value Point 
Estimate 
95% Wald 
Confidence Limits 
Intercept 0.569 0.546 1.087 0.30 NA NA NA 
AFP 1.253 0.488 6.601 0.01 12.246 1.811 82.790 
Metastatic 
Disease -1.253 0.543 5.323 0.02 0.082 0.010 0.686 
Prior 
Surgery 1.049 0.539 3.798 0.05 8.155 0.988 67.320  
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 Based on the final model comparing the Wald chi-square test statistics, both high 
AFP levels and having a prior surgery were found to have a positive association on 
FGF19 IHC status and were found to be statistically significant (p-value = .01, .05 
respectively).  Metastatic disease was found to have a statistically significant negative 
association on FGF19 IHC (p-value = .02).   
 When comparing the odds ratio for each risk factor, only AFP levels remained 
significant since the lower limit of 95% confidence interval was not less than 1.  The 
point estimate suggests that with a high AFP value (>20 ng/mL), there is a 12-fold 
chance of having a positive FGF19 IHC value.  The confidence limit was quite large 
(1.18-82.79) due to the fact that the sample size was small (45).   The point estimates for 
metastatic disease and prior surgery on FGF19 IHC status were not significant since the 
lower limit of the confidence intervals were less than 1 (0.01 and 0.99, respectively); 
however the trend for prior surgery was stronger with the lower limit just slightly less 
than 1.  This suggests that there was an 8-fold chance, if you had a prior surgery, of 
having a positive FGF19 IHC value. Although metastatic disease was not significant, the 
point estimate suggests that if a subject has metastatic disease, the odds of having a 
positive FGF19 IHC value were 0.08 as compared to subjects who do not have metastatic 
disease.  
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DISCUSSION 
 
 The aim of this study was to investigate the association of serum AFP levels and 
FGF19 IHC tumor status in advanced HCC patients. HCC is a complex disease and little 
consensus has been obtained universally on how to classify these patients.11   While 
treatment options are limited, new targeted agents, such as FGFR4/FGF19 inhibitors, are 
currently in clinical development so it is important to more thoroughly understand these 
patients to better inform treatment options once additional options become available.  
Findings from this study suggest that high serum AFP levels could be a relevant pre-
screen or surrogate for the FGF19 tumor marker and guide treatment for targeted 
therapies in development such as FGFR4 inhibitors.   
The study population as described in Table 4 was representative of HCC patients 
worldwide in terms of sex, etiology, and age.  The disease primarily affects men, and 
84% of the subjects analyzed in this study were men.4 The HCC etiology predominantly 
was viral (48.9% HBV and 8.9% HCV) which is generalizable to the worldwide 
breakdown.4 Lastly, the average age was 59.8 years old in this study, which is slightly 
younger than the average age at HCC diagnosis (65 years old), but there has been a recent 
shift toward diagnosis at an earlier age that could account for this difference.25 
Additionally, the youngest patient enrolled at 18 years, could have pulled the average 
down.  Therefore, this study represents a generalizable population of HCC patients with 
respect to age, HCC etiology, and gender.   
Elevated AFP levels have been found to be associated with poor outcomes or a 
worse prognosis in HCC patients compared to those with normal or low levels.19 Results 
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from both the univariate and multivariate analyses showed that there was a statistically 
significant association between the two variables, AFP and FGF19 tumor status.  Those 
subjects with high serum AFP levels (>20 ng/mL) had a significantly higher chance of 
also having a positive (≥1%) FGF19 IHC status.  Specifically, AFP levels were predictive 
of FGF19 IHC tumor status in this study population and the strength of this relationship 
is strong (twelve fold).  
There have been many studies over the years that have studied the clinical role of 
AFP in HCC patients, but very few have actually investigated the prognostic impact of 
AFP levels.20   The findings suggest that if high AFP levels are in fact predictive of poor 
prognoses, then patients with positive FGF19 IHC status are worse off than those that are 
negative.  These results make sense given the FGFR4/FGF19 pathway is considered to be 
an oncogenic driver and contributes significantly to HCC progression.24 Results could 
also suggest that the FGFR4/FGF19 pathway may regulate AFP levels.  
 AFP levels were the only risk factor that showed a statistically significant 
correlation with FGF19 IHC status in the multivariate stepwise logistic regression, but 
there were trends in the analysis for both metastatic disease and prior surgery.  With 
respect to metastatic disease, the chi-square test static showed a statistically significant 
negative association with FGF19 IHC status.  The negative relationship is 
counterintuitive given the presence of metastatic disease is an HCC risk factor, but the 
strength of the association was weak and not significant.  Additionally, prior surgery 
showed a trend in association with FGF19 IHC status.  This would suggest that patients 
who have had one or more liver resections or TACE procedures were more likely to also 
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be FGF19 IHC positive; but despite having a stronger relationship (8.155), it was not still 
significant.  These two findings may be explained by the study population.  Since the 
study only included advanced stage HCC patients, it may have been associated with the 
status of the disease at inclusion in the study more than FGF19 IHC status.  It could also 
be due to the small sample size.     
Studies have shown that tumor size can be a confounding factor to AFP levels 
indicating that tumor size has a significant impact on outcome. 19 The results in this study 
showed that there was not a significant difference in tumor size between the FGF19 
positive and FGF19 IHC negative groups, whereas there was a significant difference in 
AFP levels between the groups.  While this doesn’t provide any information regarding an 
association with FGF19 IHC status, it does help provide evidence that the findings were 
not confounded by tumor size.  Similarly, other major risk factors as described in Table 4 
did not have an association with FGF19 IHC status.  This could be due to the small 
sample size analyzed in this study.  
Limitations  
A cross-sectional study design has inherent limitations that can be noted in this 
study.  For example, a cross sectional analysis is only a snapshot of the data.  Since the 
data for the exposure and outcome are obtained simultaneously, it is difficult to 
understand whether the outcome came before the exposure and vice versa.  While the 
primary outcome variable was tumor FGF19 IHC tumor expression status and the 
primary predictor variable for this study was serum AFP levels, this relationship could 
reverse but causation was not investigated given the limitations of a cross-sectional study 
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design.  Also, AFP levels could have been different if measured at a various points in 
time over the course of HCC progression, which could have impacted the strength of the 
association of the data.   
Baseline FGF19 IHC status and AFP levels could also have been measured at 
different time points since the study allowed for archival tissue to be submitted for 
FGF19 IHC testing.  Therefore the biopsy or resection may have occurred at a much 
different point in time that the AFP levels that were measured within locally at baseline.  
AFP levels may or may not have changed as a result of the advanced disease population.  
However one would expect to show less of an association between the two groups of 
FGF19 IHC status if the AFP levels were driven only by the advanced stage in disease.   
The study population was also bound by the selection criteria from the Phase 1 
Study; therefore, the analysis could not include other important HCC risk factors such as 
performance status or liver function (as measured by Child’s Pugh score).  Performance 
status is known to have a significant effect on a patient’s outcome, regardless of diease.13 
The study inclusion criteria limited to fit HCC patients since inclusion criteria specified 
an ECOC status of 0-1 for enrollment into the Phase 1 study.  Because subjects with a 2-4 
status were excluded from the study, this study could not measure whether the 
performance played a role in the results.  Additionally, only HCC patients with adequate 
liver function as noted by the Child’s Pugh A inclusion criteria were enrolled in the study 
and consequently included in the analysis.   Because of the complex interaction of the 
liver cirrhosis with HCC, there was not a way to understand whether the degree of liver 
damage had an effect on the AFP levels.   
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Future Directions 
The small sample size was noted as a limitation in the study design.  Because the 
phase 1 study is still ongoing, the next step would be to re-analyze the study population 
after the study was fully enrolled.  It would be informative to understand whether the 
strength of the association remains and whether or not the confidence interval become 
more narrow with the increased sample size.  Also, the increased sample size could help 
better define the relationship of metastatic disease and prior surgery to FGF19 IHC status.  
Lastly, with a larger sample size, various AFP cutoffs could be explored in addition to 20 
ng/mL to investigate if the cutoff affects the relationship to FGF19 tumor expression.   
Considering most of the modes of classification for HCC patients do not include a mixed 
population of both early and late stage disease, another possibility would include 
investigating the association of AFP and FGF19 IHC status in a mixed HCC population 
to see if results are similar.      
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CONCLUSION 
In conclusion, this study provided useful information to better understand serum 
AFP levels in a molecular subset of HCC patients. The limitations described above have 
made it so that the results may not be entirely conclusive; however, they provide a good 
starting point for future studies. The results need to be replicated with a larger patient 
population after enrollment is complete for the Phase 1 study and could prove to be 
helpful in the clinical setting if similar conclusions are drawn. 
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